Abstract: The use of inhaled, fixed-dose, long-acting muscarinic antagonists (LAMA) combined with long-acting, beta 2 -adrenergic receptor agonists (LABA) has become a mainstay in the maintenance treatment of chronic obstructive pulmonary disease (COPD). One of the fixed-dose LAMA/LABA combinations is the dry powder inhaler (DPI) of umeclidinium bromide (UMEC) and vilanterol trifenatate (VI) (62.5 µg/25 µg) approved for once-a-day maintenance treatment of COPD. This paper reviews the use of fixed-dose combination LAMA/LABA agents focusing on the UMEC/VI DPI inhaler in the maintenance treatment of COPD. The fixed-dose combination LAMA/LABA inhaler offers a step beyond a single inhaled maintenance agent but is still a single device for the COPD patient having frequent COPD exacerbations and persistent symptoms not well controlled on one agent. Currently available clinical trials suggest that the once-a-day DPI of UMEC/VI is well-tolerated, safe and non-inferior or better than other currently available inhaled fixeddose LAMA/LABA combinations for COPD.
Introduction
Chronic obstructive pulmonary disease (COPD) is a syndrome caused by a combination of host factors, genetic susceptibilities and environmental exposures to injurious agents like tobacco smoke. It is characterized by poorly reversible airway constriction, chronic inflammation, and structural changes leading to loss of elastic recoil and air trapping. 1 COPD is a leading cause of death, disability, and health-care costs. As a syndrome, it presents with many different phenotypes. Along with inhaled corticosteroids (ICS), bronchodilators including short-acting and long-acting beta 2 receptor agonists (B2RA) as well as muscarinic receptor antagonists (MRA) play an important role in the treatment of the various COPD phenotypes. Recent reviews and meta-analyses have concluded that the combination of a fixed-dose, long-acting B2RA (LABA) combined with a long-acting MRA (LAMA) is an effective strategy for improving and maintaining lung function in COPD patients. [2] [3] [4] [5] Two reports, including a systematic review and meta-analysis and a Cochrane systematic review, have concluded that the use of a fixed-dose combination (FDC) inhaler that includes a LAMA and LABA results in fewer COPD exacerbations than a LAMA alone or a FDC of ICS with a LABA. 6, 7 The first systematic review and meta-analysis evaluated 18 studies (making up a total of 23 trials) with a total of 20,185 patients. 6 Trough forced expiratory volume in 1 second (FEV 1 ) at week 12 was significantly improved by the use of combined FDC LAMA/LABA compared to either a LAMA alone or a FDC ICS/LABA (0.07 L and 0.08 L, respectively, both P<0.0001). The FDC LABA/LAMA significantly (P<0.0001) improved dyspnea scores compared to a LAMA alone but not compared to the FDC ICS/LABA at 12 weeks. Severe to moderate COPD exacerbations were reduced with the FDC LABA/LAMA compared to the FDC LABA/ICS (rate ratio (RR) 0.82, 95% CI, 0.75-0.91).
The FDC LABA/LAMA significantly reduced rescue medication use compared to both the LAMA alone (P<0.001) and the FDC ICS/LABA (P=0.001). There was no difference in adverse events (AE) incidence between LAMA/LABA and LAMA alone but when LAMA/LABA was compared to ICS/ LABA there was a lower AE incidence (RR 0.94, 95% CI, 0.89-0.99). A marked reduction in pneumonia risk was seen with the FDC LAMA/LABA compared to FDC ICS/LABA (RR 0.59, 95% CI, 0.43-0.81). The Cochrane review included 11 studies and 9,839 patients with COPD. 7 The studies ranged from 6 to 52
weeks and compared the use of FDC LAMA/LABA to FDC ICS/LABA treatments. A reduction in COPD exacerbations was found comparing FDC LAMA/LABA to FDC ICS/LABA (OR 0.82, 95% CI 0.70-0.96) and an increase in trough FEV 1 from baseline with a mean of 0.08 L (95% CI 0.06-0.09, P<0.0001) was seen. The risk of pneumonia was again lower with the use of FDC LAMA/LABA compared to FDC ICS/LABA (OR 0.57, 95% CI, 0.42-0.79, P=0.0006). Several studies have explored withdrawing an ICS in stable patients with moderate to severe COPD. 8, 9 Magnussen et al 8 studied 2,485 COPD patients with a history of COPD exacerbations in a 12-month, doubleblind, parallel-group study. Patients were placed on a LAMA, ICS, and LABA for a six-month run-in period called the WISDOM Trial. They were then randomized to continue the triple therapy or to the withdrawal of just the ICS and were to continue the LAMA and LABA inhaler over the 12 weeks of the study. There was no significant difference in the rate of COPD exacerbation with the study meeting the prespecified noninferiority criterion. The trough FEV 1 was 0.038 L greater (P<0.001) in the glucocorticoid-withdrawal group but this difference is unlikely to be clinically important. The rate of pneumonia was 5.8% for those that continued triple inhaled therapy and 5.5% for those that had the ICS withdrawal. 8 A more recent study of COPD patients with infrequent exacerbations but who had been on long-term triple (LAMA, LABA, ICS) therapy were randomized to remove the ICS. Fixed-dose combination dry-powder inhaler of umeclidinium and vilanterol
The LAMA umeclidinium bromide (UMEC) and the LABA vilanterol trifenate (VI), both delivered as a once-a-day DPI, have been independently shown to be effective maintenance treatments for COPD. [13] [14] [15] [16] [17] [18] [19] [20] 
Review and methodology
The Food and Drug Administration (FDA) website accessdata.gov was used to determine their approved inhalers. Inhalers approved by the European Medicines Agency (EMA) were confirmed using the https://www.ema. europa.eu website and Canadian approved drugs were confirmed using the website health-products.canada.ca. Because of several new trials since the last review, a new extensive review of LAMA, LABA/LAMA, VI, vilanterol, UMEC, umeclidinium, and COPD was performed using https://www.ncbi.nlm.nih.gov/pubmed and https://scholar.google.com. Papers found were also crossreferenced for additional clinical trials of UMEC/VI inhaled treatment and COPD. In addition, completed and published clinical trials with UMEC/VI and COPD were reviewed at https://clinicaltrials.gov. Several new trials using UMEC/VI in COPD were found since the last reviews and both older clinical trials and these newer trials are included in this summary. decrease in creatinine clearance resulted in a 3% decrease in the apparent inhaled clearance of UMEC. No UMEC and VI interactions were seen or modeled in this population pharmacokinetics study. 25 A safety and pharmacokinetic study (NCT00976144) in 16 healthy, male, Japanese non-smokers evaluated single inhaled doses of placebo, UMEC 500 µg, VI 50 µg, and various combinations (placebo and placebo, UMEC 500 µg and VI 50 µg) in four different sequences over four periods. 26 The exposures were well tolerated with no trends observed in supine heart rates during the UMEC or VI maximum serum concentrations. 26 Pharmacokinetic evaluations resulted in rapid absorption with maximum systemic levels for both VI and UMEC in about 5 min with rapid elimination and a halflife (T½) of 0.42 (0.36-0.49) hours for VI and a T½ of 1.56 (1.29-1.90) hours for UMEC and only a small amount of prolongation was noted when UMEC and VI were given together. The T½ of UMEC when given with VI was 1.78 (1.17-2.70) hours and that of VI when given with UMEC was 0.71 (0.52-0.97) hours. 26 Little drug interaction was demonstrated in single doses alone or in combination and clinically very high doses were well tolerated.
Pharmacology
Another single-center trial of pharmacokinetics and safety (NCT01899638) evaluated healthy, non-smoking, male and female (1:1) Chinese subjects (N=20) with each subject getting a sequence of three of five treatments (UMEC/VI 62.5/25 µg, UMEC/VI 125/25 µg, UMEC 62.5 µg, UMEC 125 µg or VI 25 µg) once daily for 10 days. 27 The time to maximum serum VI levels was 0.08 hours after 25 µg of VI regardless of UMEC dose (0, 62.5 and 125 µg). The time to maximum UMEC serum level also was fast and similar at 0.08 hours after both doses with or without VI. No pharmacokinetic evidence of drug interaction was seen when UMEC and VI were given together. Twelve subjects had ≥1 AEs with the most common being "chest discomfort." No vital sign or electrocardiogram abnormalities were noted. 27 A 28-day, randomized, multicenter, double-blind, parallel-group, placebo-controlled trial of daily UMEC (500 µg) in combination with VI (25 µg) was performed in 51 male and female patients with COPD over the age of 40 years. 28 UMEC/VI was non-inferior to placebo in weighted pulse rate determinations on Day 28 over hours 0-6 post-dosing. There were no differences seen between UMEC/VI and placebo in blood pressure, minimum or maximum pulse rates or electrocardiogram QTc intervals. No correlations between maximum serum concentrations of either VI or UMEC and pulse rates on Day 28 were seen despite the very high UMEC dose.
28
A pharmacokinetic study in nine patients with severe renal impairment (creatinine clearance <30 mL/minute) matched to healthy volunteers and exposed to a single inhaled dose of UMEC (125 µg) or UMEC/VI (125/25 µg) did not demonstrate clinically relevant differences in VI or UMEC serum concentrations. 29 Similarly, patients with moderate hepatic impairment were compared to normal volunteers (total N=18) and given either a single dose of inhaled UMEC (125 µg) or UMEC/VI (125/25 µg) and then the other after a 7-14-day washout period. 30 No significant differences in serum levels were seen between the patients with moderate liver disease and the normal volunteers. Dose adjustments of inhaled UMEC/VI do not appear to be indicated for COPD patients with renal or hepatic impairment. An open-label study (NCT01128634) that randomized schedules evaluated the moderate p-glycoprotein transporter and cytochrome P450 isozyme 3A4 (CYP3A4) inhibitor verapamil in patients also given dry powder inhaled UMEC. UMEC serum levels and its safety profile were evaluated.
31 Subjects (N=32) were healthy male and female non-smokers (18-65 years old). The subjects underwent two schedules of treatment. One was 8 days of UMEC 500 µg inhaled daily alone followed by daily inhaled UMEC 500 µg and a daily single oral tablet of 240 mg verapamil for 5 days. The second schedule was similar to the first except that the subjects were exposed to inhaled UMEC/VI (500/25 µg) daily for 8 days followed by continuation of UMEC/VI (500/25 µg) and oral verapamil 240 mg daily for 5 days. There was no increase in systemic levels of UMEC with VI compared to UMEC alone. Maximum UMEC serum concentrations were similar with or without verapamil exposure. The area under the curve for serum levels of UMEC increased by only 1.4-fold with verapamil compared to without. The combination of inhaled UMEC or UMEC/VI was well tolerated with or without daily exposure to the moderate P-glycoprotein transporter and CYP3A4 inhibitor verapamil.
31
A comparison study of possible electrocardiogram and correlated QTc interval changes after exposure to the antibiotic moxifloxacin and to inhaled UMEC and UMEC/VI was performed. 32 Male and female healthy non-smokers aged 18-65 years with normal electrocardiograms were included (N=103). Subjects received, randomly, four out of five possible treatments for 10 days including DPI UMEC 500 µg + Day 10 placebo tablet, daily inhaled UMEC/VI 125/25 µg + Day 10 placebo tablet, UMEC/VI 500/100 µg + Day 10 placebo tablet, placebo via Ellipta ® DPI + Day 10 placebo tablet, and placebo inhaler + Day 10 moxifloxacin 400 mg tablet. There were no clinically significant QTc interval changes noted during the 10 days with inhaled UMEC/VI 125/25 µg or UMEC 500 µg compared to placebo. The supra-therapeutic inhaled dose of UMEC/VI of 500/100 µg was associated with a small change in corrected QTc interval of 6.4 ms (95% CI, 4.3-8.5) at 10 min, 8.2 ms (95% CI, 6.2-10.2) at 30 min and returned to placebo intervals rapidly after that time. This compares to a maximum change in corrected QTc interval of 9.7 ms (95% CI, 8.0-11.4) at 4 h after 400 mg of oral moxifloxacin. 32 No cardiac safety signal was noted in this study. The current data review is consistent with an earlier systematic review of the efficacy and safety of the fixed-dose combination DPI of UMEC/VI involving 11 trials from 10 studies (9,609 patients). It concluded that UMEC/VI had excellent evidence of efficacy and showed "superior efficacy" to its monocomponents, tiotropium and fluticasone/combination inhalers with "reduced" safety concerns compared to comparitors. 33 The safety of fixed-dose LABA/LAMA inhalers has also been recently reviewed. 34 The analysis of currently available data suggests a favorable cardiovascular safety profile for FDC LAMA/LABA inhalers in the COPD population. 34 In the absence of new, larger, real-life and post-marketing studies to evaluate for rare low-frequency safety issues, FDC LAMA/LABA inhalers including UMEC/VI appear safe and efficacious.
Clinical efficacy of fixed-dose combination inhaler UMEC/VI
Based on the previously noted studies that demonstrated efficacy in COPD from both the LAMA UMEC and the LABA VI individually with a DPI device, it was logical and likely to improve drug adherence by putting these two compounds together into a single inhaler. The Ellipta ® Inhaler was utilized. Table 1 summarizes most currently available fixed-dose combined B2RA and MRA inhalers and nebulized products used in the treatment of COPD. Several reviews have summarized older clinical data on the dry-powder inhaled a fixed dose of UMEC/VI in COPD treatment. [35] [36] [37] Similarly, a pooled analysis of older data of elderly patients with COPD showed efficacy of UMEC/VI in this group. 38 The earliest studies (see Those patients that showed FEV 1 response to either VI or UMEC monotherapy were more likely to respond to UMEC/VI combination with greater improvement compared to either monotherapy. The remaining efficacy trials in Table 2 demonstrated that once-a-day UMEC/VI (62.5/25 µg) was better than a combined DPI of twice-a-day salmeterol/fluticasone propionate (50/250 or 50/500 µg combinations) in improving Glycopyrronium is the same as glycopyrrolate which is the United States Adopted Name (USAN).
Abbreviations: B2RA, beta 2 receptor agonist; MRA, muscarinic receptor antagonist; LAMA, long-acting MRA; LABA, long-acting B2RA; SAMA, short-acting MRA; SABA, short-acting B2RA; ICS, inhaled corticosteroid; FF, fluticasone furoate; Bec, beclomethasone; NA, not applicable; q6h, every 6 h; bid, twice-a-day; qd, once-a-day, Neb, nebulized; MDI, metered dose inhaler; SDMI, spring-driven mist inhaler; DPI, dry powder inhaler. Albertson 12-week trough FEV 1 . 3, 47 In addition, a series of studies compared UMEC/VI (62.5/25 µg) once daily to the LAMA tiotropium dry powder combined with the LABA indacaterol, the LAMA glycopyrronium also known as glycopyrrolate (GLY) combined with indacaterol (IND) as a DPI and tiotropium (TIO) combined with the LABA olodaterol (OLO) delivered by a spring-driven mist inhaler (Respimat ® ) once daily. [48] [49] [50] [51] In a 12-week, randomized, blinded, triple-dummy, parallel-group, non-inferiority trial, UMEC/VI (62.5/25 µg) by DPI once daily was compared to with once-daily TIO (18 µg) by DPI and once-daily indacaterol (IND; 150 µg) by DPI. 28 The An open-label, randomized, two-period, cross-over study of two different LAMA/LABA inhalers in patients with COPD compared once-daily UMEC/VI (62.5/ 25 µg) by DPI to once-daily TIO/OLO (5/5 µg) by spring-driven "soft" mist inhaler (Respimat ® ) each for 8 weeks with a 3-week washout. 30 The UMEC/VI treatment was non-inferior at week 8 trough FEV 1 . It was statistically superior to TIO/OLO in the intent-to-treat population with an increase in week 8 trough FEV 1 of 0.052 L (95% CI of 0.028-0.077 L; P<0.001). Clinical meaningful increases in the trough from baseline FEV 1 of 0.100 L or more at week 8 were twice as likely to be reached with the use of UMEC/VI compared to TIO/ OLO treatments. Efficacy data from these trials demonstrated that the once-daily dry powder UMEC/VI (62.5/25 µg) was non-inferior or superior to the comparison treatment (Table 2) . A 12-week study on exercise tolerance demonstrated statistically increases with both 125/25 µg and 62.5/25 µg UMEC/VI inhaler doses compared to placebo inhaler in COPD patients with access to as-needed salbutamol. 41 However, a recent study that evaluated UMEC/VI (62.5/25 µg) compared to placebo in COPD patients with access to as-needed albuterol or ipratropium inhalers failed to show an improved in-exercise endurance testing despite improved trough FEV 1 at week 12. 44 Utilizing US health insurance plan data from 2013-2015, a large retrospective study examined COPD patients initiated on tiotropium or the combination UMEC/ VI and compared time to progression to triple-inhaled therapy of a LAMA, a LABA and an ICS. 52 The study found that starting patients on tiotropium (N=35,357) was associated with an 87% higher risk of ending in triple therapy than those patients started on UMEC/VI (N=2407) (HR=1.87, 95% CI, 1. Another review of the use of an ICS in COPD patients has suggested that they should not be used as a stand-alone maintenance therapy but rather used with a long-acting bronchodilator (LAMA or LABA). 61 In this review, patients with frequent or severe COPD exacerbations after adherence to the use of maintenance bronchodilators particularly in patients with a history of asthma or blood eosinophils that are >300 cells/µL are most likely to benefit from ICS. 61 The risk of pneumonia in COPD patients treated with an ICS is higher in older age patients, those patients demonstrating greater fragility, patients with lower body mass index and in those patients with blood eosinophils <100 cells/µL. 61 A Cochrane review has confirmed that the use of an ICS in COPD patients is associated with an increased risk of pneumonia events but without significant increase in mortality. 62 As noted, many COPD patients on ICS maintenance therapy tolerate the withdrawal of the ICS and the tolerance of this withdrawal may be dependent on disease severity, eosinophil counts, atopy, history of asthma, continued use of long-acting bronchodilators and whether there is evidence of hyper-responsive airways. 63 Adding This study emphasizes that patient attitude toward a particular inhaler and their experiences using it may affect therapy adherence. 69 A recent systematic review of 16 studies of both asthma and COPD patients reported that inhalation device errors were associated with worse disease outcomes. 70 Education time invested in improving inhalation technique in COPD can improve health outcomes. However, improved clinical outcomes with this device over other delivery devices with UMEC/VI have not been shown to date.
Conclusions
The fixed-dose DPI LAMA/LABA inhaler with UMEC and VI (62.5/25 µg) offers an important option in a stepwise treatment approach to the COPD patient. The use of UMEC/VI DPI in COPD has significant data supporting its efficacy and defining its risks. It is well tolerated, and the Ellipta ® delivery system is liked by COPD patients.
Improved drug use adherence and reduced drug delivery errors are expected with the Ellipta ® device based on studies available. FDC inhalers that contain LAMA/ LABA components are a mainstay in the treatment of COPD. These combination agents routinely result in lower total co-payments for patients with COPD in managed-care and straight insurance programs.
